MedTrace Logo

Primary Sclerosing Cholangitis in Children

NCT04181138 · Status: RECRUITING · Type: OBSERVATIONAL · Enrollment: 1000

Last updated 2025-09-08

No results posted yet for this study

Summary

Primary sclerosing cholangitis (PSC) is a rare liver disease that damages the liver's bile ducts. Bile ducts are tiny tubes that carry bile from the liver to the small intestine. Bile is a liquid produced by the liver that helps us absorb and use the nutrients in the food we eat. In people with PSC, the bile backs up into the liver and will damage it, causing scarring of the liver.

The purposes of this study are to:

* Collect medical and other data to learn more about PSC, how it progresses, and identify factors that may cause the disease to progress more quickly.
* Ask questions about how PSC symptoms affect your child's life to learn more about its impact on your child's daily functioning
* Children with PSC who are seen at one of the participating clinical sites in the Childhood Liver Disease Research Network (ChiLDReN) will be asked to contribute information, DNA, and other specimens. The information and specimens will be available to investigators to carry out approved research aimed at learning more about the possible causes and long-term effects of PSC.

Conditions

  • Primary Sclerosing Cholangitis
  • Liver Diseases
  • Cholangitis, Sclerosing

Sponsors & Collaborators

  • National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)

    collaborator NIH

  • Arbor Research Collaborative for Health

    lead OTHER

Principal Investigators

  • Cara Mack, MD · Medical College of Wisconsin-Milwaukee

  • Ed Doo, MD · National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)

  • Katrina Loh, MD · National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)

  • John Magee, MD · University of Michigan

  • Lisa Henn, PhD · Arbor Research Collaborative for Health

Eligibility

Min Age
2 Years
Max Age
25 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2021-12-30
Primary Completion
2029-05-31
Completion
2029-05-31

Countries

  • United States
  • Canada

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04181138 on ClinicalTrials.gov